Do We Optimize Vitamins and Folic Acid Treatment in Dialysis Patients? New and Old Challenges
DOI:
https://doi.org/10.53555/hsn.v6i2.1232Keywords:
Vitamin В12, Folic acid, hemodialysisAbstract
SUMMARY: It has been known for many years that the administration of Folic acid (FA) and Vitamin B12 is a necessary replacement therapy for chronic renal failure patients on periodic hemodialysis due to a number of dietary restrictions in these patients. There is a lot of writing, talking and research about Vitamin B12 and FA deficiency. However, there are only sporadic publications on Vitamin B12 and FA hypervitaminosis and its consequences. ABOPHOLIC META is available in Bulgaria since 2011, and it has been used in the Dialysis Department at Sveta Anna Hospital, Sofia ever since. It is noteworthy that during the years of use of this preparation, using additional amounts of Vitamin B12 is becoming rarer and in fewer patients.
The purpose of this follow-up is to:
Determine whether patients maintain stable (within the reference range) serum levels of Vitamin B12 and FA during a 6-month period of ABOPHOLIC META administration. Confirm the hypothesis of a real difference (association) between the outcomes in patients with good compliance of both sexes.
Material and methods:
57 dialysis patients were followed up in the Dialysis Department at UMHAT “Sveta Anna”, Sofia. Hemoglobin, Vitamin B12 and FA results were compared. The methods of prospective follow-up and the following Data analyses were used: t-Test: Two-Sample Assuming Unequal Variances, Descriptive statistics: point estimates of parameters-finding of averages, Deductive statistics, Parametric analysis.
Abbott Diagnostics’ CLIA Aliniy ci-series was used as the method of testing of Vitamin B12 and FA serum levels.
Hemoglobin was tested by a colorimetric method.
Conclusions: At a dose of ABOPHOLIC META 1 tab/day, the patients maintained stable Vitamin B12 and FA serum levels and no further Vitamin B12 containing preparation was required. There were no patients with FA level above the reference range. There was a real difference (association) between the results of patients of both sexes with good compliance for both Folic acid (P-value = 0.030) and Vitamin B12 (P-value = 0.032).
No similar data on available sex differences are reported in the scientific literature. This is the first time this has been proven in those patients.
Downloads
References
(1). Go, A.S.; Chertow, G.M.; Fan, D.; McCulloch, C.E.; Hsu, C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 2004, 351, 1296–1305. [CrossRef] [PubMed]
(2). Foley, R.N.; Parfrey, P.S.; Sarnak, M.J. Epidemiology of cardiovascular disease in chronic renal disease. J. Am. Soc. Nephrol. 1998, 9, S16–S23. [CrossRef] [PubMed]
(3). Jha, V.; Garcia-Garcia, G.; Iseki, K.; Li, Z.; Naicker, S.; Plattner, B.; Saran, R.; Wang, A.Y.; Yang, C.W. Chronic kidney disease: Global dimension and perspectives. Lancet 2013, 382, 260–272. [CrossRef]
(4 ). McCullough, P.A.; Steigerwalt, S.; Tolia, K.; Chen, S.C.; Li, S.; Norris, K.C.; WhaleyConnell, A.; KEEP
Investigators. Cardiovascular disease in chronic kidney disease: Data from the Kidney Early
Evaluation Program (KEEP). Curr. Diab. Rep. 2011, 11, 47–55. [CrossRef]
(5). Ekdahl, K.; Soveri, I.; Hilborn, J.; Fellström, B.; Nilsson, B. Cardiovascular disease in
hemodialysis: Role of the intravascular innate immune system. Nat. Rev. Nephrol. 2017, 13, 285–296. [CrossRef] [PubMed]
(6). McCully, K.S. Homocysteine and vascular disease. Nat. Med. 1996, 2, 386–389. [CrossRef] [PubMed]
(7). Chrysant, S.G.; Chrysant, G.S. The current status of homocysteine as a risk factor for
cardiovascular disease: A mini review. Expert. Rev. Cardiovasc. Ther. 2018, 16, 559–565. [CrossRef]
(8). Robinson, K. Renal disease, homocysteine, and cardiovascular complications. Circulation
, 109, 294–295. [CrossRef]
(9). Suliman, M.E.; Lindholm, B.; Barany, P.; Qureshi, A.R.; Stenvinkel, P. Homocysteinelowering is not a
primary target for cardiovascular disease prevention in chronic kidney disease patients. Semin. Dial. 2007, 20, 523–529. [CrossRef]
(10). Heinz, J.; Kropf, S.; Luley, C.; Dierkes, J. Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: A meta-analysis. Am. J. Kidney Dis. 2009, 54, 478–489. [CrossRef]
(11). Cianciolo, G.; La Manna, G.; Colì, L.; Donati, G.; D’Addio, F.; Persici, E.; Comai, G.;
Wratten, M.; Dormi, A.; Mantovani, V.; et al. 5-methyltetrahydrofolate administration is associated with prolonged survival and reduced inflammation in ESRD patients. Am. J. Nephrol. 2008, 28, 941–948. [CrossRef] [PubMed]
(12). Cianciolo, G.; De Pascalis, A.; Di Lullo, L.; Ronco, C.; Zannini, C.; La Manna, G. Folic Acid and Homocysteine in Chronic Kidney Disease and Cardiovascular Disease Progression: Which Comes First?
Cardiorenal. Med. 2017, 7, 255–266. [CrossRef] [PubMed]
(13). Marti, F.; Vollenweider, P.; Marques-Vidal, P.M.; Mooser, V.; Waeber, G.; Paccaud, F.; Bochud, M. Hyperhomocysteinemia is independently associated with albuminuria in the population-based
CoLaus study. BMC Public Health. 2011, 11. [CrossRef] [PubMed]
(14). Ponte, B.; Pruijm, M.; Marques-Vidal, P.; Martin, P.Y.; Burnier, M.; Paccaud, F.;Waeber, G.; Vollenweider, P.; Bochud, M. Determinants and burden of chronic kidney disease in the population-based CoLaus study: A cross-sectional analysis. Nephrol. Dial. Transpl. 2013, 28, 2329–2339. [CrossRef]
[PubMed]
(15). Soohoo, M.; Ahmadi, S.F.; Qader, H.; Streja, E.; Obi, Y.; Moradi, H.; Rhee, C.M.; Kim, T.H.; Kovesdy, C.P.; Kalantar-Zadeh, K. Association of serum vitamin B12 and folate with mortality in incident hemodialysis patients. Nephrol. Dial. Transpl. 2017, 32, 1024–1032. [CrossRef] [PubMed]
(16). Fife J, Raniga S, Hidere P N and Frizelle F A (2009) Folic Acid supplementation and colorectal cancer risk: a meta analysis. Colorectal Disease. 13, 132-137
(17). Kim, Y.I. (2007) Folate and colorectal cancer: An evidence-based critical review. Molecular Nutrition and Food Research. 51: 267-292
(18).Albert, C.M., Cook, N.R., Gaziano, J.M. et al (2008) Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease. A randomized trial. The Journal of the American Medical Association. 299(17) 2027-2036
(19).Guideline for Supplementation of Folic Acid in Intermittent Haemodialysis & Peritoneal Dialysis- Beaumont Hospital- Dublin-Department of Nephrology, Dialysis and Transplantation
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 International Journal For Research In Health Sciences And Nursing (ISSN: 2208-2670)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
In consideration of the journal, Green Publication taking action in reviewing and editing our manuscript, the authors undersigned hereby transfer, assign, or otherwise convey all copyright ownership to the Editorial Office of the Green Publication in the event that such work is published in the journal. Such conveyance covers any product that may derive from the published journal, whether print or electronic. Green Publication shall have the right to register copyright to the Article in its name as claimant, whether separately
or as part of the journal issue or other medium in which the Article is included.
By signing this Agreement, the author(s), and in the case of a Work Made For Hire, the employer, jointly and severally represent and warrant that the Article is original with the author(s) and does not infringe any copyright or violate any other right of any third parties, and that the Article has not been published elsewhere, and is not being considered for publication elsewhere in any form, except as provided herein. Each author’s signature should appear below. The signing author(s) (and, in
